AIHTA - News

Newsletter

Note: this content is only available in German.

Inhalt

Zur Druckversion...

Adobestock-329115246-von-mike-fouque-klein16

©stock.adobe.com

Announcement

Covid-19: HSS/ Horizon Scanning Living Document (v15 June 2021)

The establishment of a HSS/ Horizon Scanning System for Covid19 interventions has the intentions of informing health policy makers at an early stage which interventions (vaccinations and drugs) are currently undergoing clinical trials and to monitor them over the next few months in order to support evidence-based purchasing if necessary. The products are monitored with regard to the status of the clinical studies up to approval and finally evaluated for their benefit and harm.

All work steps are conducted in close international (European) cooperation.

Publications:

Policy Brief No. 002: http://eprints.aihta.at/1234/

Contact: Claudia Wild

More...

Adobestock-329115246-von-mike-fouque-klein15

©stock.adobe.com

Announcement

Bamlanivimab monotherapy and as combination therapy (with etesevimab) for Covid-19

The clinical evidence for bamlanivimab as monotherapy and in combination with etesevimab consists of a published 5-arm RCT with an adaptive study design (part of the patient population from phase 2 of BLAZE-1) with final results from 592 patients with mild-to-moderate SARS-CoV2 disease in an ambulant setting. In addition, unpublished results are available from the 3-arm phase 3 part of BLAZE-1 in high-risk patients with mild to moderate SARS-CoV2 disease. There are currently several registered ongoing clinical trials evaluating bamlanivimab as monotherapy and in combination with etesevimab compared to standard of care or other investigational neutralising monoclonal antibodies in the outpatient setting. The unpublished results must be interpreted with caution until a peer-reviewed publication is available. A conclusive assessment is not possible based on the current data.

Publication: Policy Brief No. 009: http://eprints.aihta.at/1314/
Contact: Claudia Wild

More...

Adobestock-329115246-von-mike-fouque-klein14

©stock.adobe.com

Announcement

Combinationtherapy Casirivimab plus Imdevimab (REGN-COV2) for the treatment of covid-19

The clinical evidence for a combination therapy with casirivimab plus imdevimab (REGN-COV2) consists of a published RCT with an adaptive trial design (part of the phase 1/ 2 patient population) with preliminary results in 275 patients with mild-to-moderate SARS-CoV2 disease and the unpublished phase 3 part of the same RCT in 4,567 non-hospitalised high-risk adults with mild-to-moderate SARS-CoV2 disease. Both studies suggest that REGN-COV2 can reduce follow-up treatment, which is particularly relevant for patients at high risk of disease progression, and that REGN-COV2 has a favourable safety profile. However, a final assessment is not possible based on the current data.

Publication: Policy Brief No. 008: http://eprints.aihta.at/1313/
Contact: Claudia Wild

More...

Announcement

Transparency: Sponsoring of patient initiatives, Update

As patient organisations continue to professionalise and expand their activities, their need for financial resources is also increasing, which is often covered by pharmaceutical companies. In order to make these financial flows more transparent, the pharmaceutical industry has responded with voluntary commitments to greater transparency. The AIHTA (then still known as LBI-HTA) systematically analysed this data on sponsorship of patient initiatives for the first time in 2014 and aims to carry out consistent and ongoing monitoring of payments. The present fourth update of the systematic analysis investigated the extent to which patient initiatives in Austria were financially supported by pharmaceutical companies in 2019.

In 2019, only 39 out of a total of 115 PHARMIG member companies disclosed financial contributions to patient initiatives. Compared to 2018, the disclosure rate dropped from 43 to 34 per cent, while at the same time there was a significant increase in the amount of money declared by 37 per cent to around 2.3 million euros. In 2019, the areas of haemato-oncology (around 16 per cent of the total) and haemophilia (around 13 per cent) received the largest share, followed by lung diseases, diabetes and metabolic diseases.

Publication: Policy Brief No. 007: https://eprints.aihta.at/1308
Contact: Ozren Sehic

More...

©stock.adobe.com

Announcement

Horizon Scanning in Oncology - Fact Sheets

We are pleased to introduce our four new HSO Fact Sheets.

Fact Sheet No. 47 (April 2021)
Azacitidine (Onureg®) for the maintenance treatment of patients with acute myeloid leukaemia (AML)

Fact Sheet No. 48 (April 2021)
Osimertinib (Tagrisso®) as monotherapy for the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC)

Fact Sheet No. 49 (April 2021)
Venetoclax (Venclyxto®) in combination with a hypomethylating agent for the treatment of patients with newly diagnosed acute myeloid leukaemia (AML)

Fact Sheet No. 50 (April 2021)
Nivolumab (Opdivo®) in combination with ipilimumab for the first-line treatment of patients with unresectable malignant pleural mesothelioma

More...

Adobestock-329115246-von-mike-fouque-klein13

©stock.adobe.com

Announcement

Covid-19: HSS/ Horizon Scanning Living Document (v14 May 2021)

The establishment of a HSS/ Horizon Scanning System for Covid19 interventions has the intentions of informing health policy makers at an early stage which interventions (vaccinations and drugs) are currently undergoing clinical trials and to monitor them over the next few months in order to support evidence-based purchasing if necessary. The products are monitored with regard to the status of the clinical studies up to approval and finally evaluated for their benefit and harm.

All work steps are conducted in close international (European) cooperation.

Publications: